With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro. With a ...

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients, but the firm has expanded its portfolio to include additional innovative drugs in therapeutic areas ...

Amgen has its roots in providing supportive-care products to kidney disease and cancer patients. Free cash flow hovers at 40% of sales as the firm benefits from massive cost-cutting and improved ...

ZURICH, Nov 18 (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights ...

SAN FRANCISCO (CBS.MW) -- Amgen Inc. said after the bell Friday that a Phase III study shows that administering Neulasta to breast cancer patients at the beginning of the first and subsequent cycles ...

It has been about a month since the last earnings report for Amgen (AMGN). Shares have added about 0.5% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading ...

(Reuters) - Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit ...

Lawyers at Gibbons on Tuesday removed a defamation lawsuit against Amgen, the maker of Neulasta, Enbrel and other pharmaceuticals, and Lawrence Alitowski to New Jersey District Court. The suit was ...